LWAC
PFE icon

Laurel Wealth Advisors (California)’s Pfizer PFE Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$4.23M Buy
82,624
+3,066
+4% +$147K 0.42% 59
2022
Q3 		$3.48M Sell
79,558
-14,151
-15% -$688K 0.37% 72
2022
Q2 		$4.91M Sell
93,709
-2,606
-3% -$133K 0.5% 44
2022
Q1 		$4.99M Sell
96,315
-34,644
-26% -$1.8M 0.41% 57
2021
Q4 		$7.73M Buy
130,959
+33,960
+35% +$1.68M 0.6% 29
2021
Q3 		$4.17M Sell
96,999
-8,717
-8% -$386K 0.77% 22
2021
Q2 		$4.14M Buy
105,716
+12,719
+14% +$495K 0.54% 42
2021
Q1 		$3.37M Sell
92,997
-4,757
-5% -$169K 0.51% 42
2020
Q4 		$3.6M Buy
97,754
+21,932
+29% +$804K 0.53% 44
2020
Q3 		$2.64M Buy
75,822
+2,387
+3% +$83.7K 0.44% 58
2020
Q2 		$2.28M Buy
73,435
+6,745
+10% +$229K 0.42% 60
2020
Q1 		$2.07M Sell
66,690
-5,198
-7% -$177K 0.47% 53
2019
Q4 		$2.67M Sell
71,888
-15,585
-18% -$555K 0.45% 55
2019
Q3 		$2.98M Buy
87,473
+17,672
+25% +$643K 0.51% 46
2019
Q2 		$2.87M Sell
69,801
-442
-0.6% -$17.6K 0.63% 36
2019
Q1 		$2.83M Buy
70,243
+62,253
+779% +$2.49M 0.7% 31
2018
Q4 		$330K Sell
7,990
-64,246
-89% -$2.67M 0.1% 236
2018
Q3 		$3.02M Buy
72,236
+2,710
+4% +$104K 0.74% 29
2018
Q2 		$2.39M Buy
69,526
+6,027
+9% +$206K 0.64% 36
2018
Q1 		$2.14M Sell
63,499
-4,597
-7% -$158K 0.66% 36
2017
Q4 		$2.34M Buy
68,096
+8,294
+14% +$283K 0.67% 33
2017
Q3 		$2.02M Sell
59,802
-1,303
-2% -$41.9K 0.68% 32
2017
Q2 		$1.95M Buy
61,105
+1,950
+3% +$61.5K 0.69% 32
2017
Q1 		$1.92M Buy
59,155
+5,249
+10% +$165K 0.74% 27
2016
Q4 		$1.66M Buy
53,906
+18,056
+50% +$551K 0.74% 29
2016
Q3 		$1.15M Sell
35,850
-794
-2% -$26.5K 0.54% 54
2016
Q2 		$1.22M Buy
36,644
+2,703
+8% +$86.3K 0.59% 45
2016
Q1 		$954K Sell
33,941
-1,231
-3% -$35.2K 0.48% 57
2015
Q4 		$1.08M Buy
+35,172
New +$1.11M 0.56% 52

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Laurel Wealth Advisors (California)'s PFE Position: Q4 2022 in Review

Laurel Wealth Advisors (California) increased its Pfizer (PFE) stake by 3.9% in Q4 2022, buying an estimated $147K and bringing the position to 82,624 shares worth $4.23M. The position accounts for 0.42% of the portfolio, ranked #59.

Laurel Wealth Advisors (California) first reported a position in PFE in Q4 2015 and has held it in 29 quarters since. The position peaked at $7.73M in Q4 2021. 3,268 funds tracked by Wall St. Rank hold PFE as of Q4 2022.

  • Laurel Wealth Advisors (California) held 82,624 shares of Pfizer worth $4.23M as of Q4 2022.
  • Laurel Wealth Advisors (California) bought 3,066 Pfizer shares in Q4 2022, an estimated $147K.
  • Pfizer made up 0.42% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #59 holding.
  • Laurel Wealth Advisors (California) first reported a position in Pfizer in Q4 2015 and has held it in 29 quarters since.
  • Laurel Wealth Advisors (California)'s Pfizer position peaked at $7.73M in Q4 2021.
  • 3,268 funds tracked by Wall St. Rank held Pfizer as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.